(Reuters) -Drugmaker AstraZeneca lifted its annual sales and ... The new investments will expand manufacturing sites in Maryland, Texas and California and create 1,000 high-skilled jobs in the ...
The new investments will expand manufacturing sites in Maryland, Texas and California. But AstraZeneca shares have fallen nearly 6% this year, underperforming a near 9% rise in the wider European ...
AstraZeneca made headlines for several reasons on Tuesday ... The investment will also support creation of a new next generation manufacturing facility, focused on biologics, in Maryland as well as ...
Outside of Massachusetts, AstraZeneca said its expanding U.S. footprint includes a manufacturing facility for biologics in Maryland, cell therapy manufacturing capacity on the West and East Coasts ...
Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions ... a next-generation biologics manufacturing facility in Maryland, specialty manufacturing in Texas and cell ...
AstraZeneca’s expanding footprint in the US includes, among others: A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts; A next generation manufacturing facility for biologics in ...
AstraZeneca has upgraded its annual guidance ... centre in Massachusetts and a manufacturing facility for biologics in Maryland. Soriot said the investment reflects the 'attractiveness of the ...